MetaCap

GRI Bio (GRI) vs Purple Biotech (PPBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GRI Bio is the larger company by market cap ($2.4 million vs $1.9 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRI-39.46%PPBT+4.45%
+20%-11%-42%
Oct 7, 20261 yearNov 20, 2026
GRI-35.63%PPBT+14.66%
+25%-7%-39%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRI versus PPBT key metrics
MetricGRIPPBT
Share price$1.12$1.53
Market cap$2.45M$1.86M
1-day change0.00%-4.09%
P/E ratio (TTM)0.05—
EPS (TTM)$20.57$-47.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-11.96M$-26.39M
52-week high$64.12$8.90
52-week low$1.09$0.91
Distance from 52-week high-98.25%-82.87%
Analyst consensusnonenone
Avg. price target upside+1551.79%+1014.75%
Average volume218.31K1.26M
Shares outstanding2.19M1.22M
Employees310
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About GRI Bio

GRI stock →

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About Purple Biotech

PPBT stock →

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

GRI vs PPBT FAQ

Which is bigger, GRI Bio or Purple Biotech?

GRI Bio (GRI) is larger, with a market capitalization of $2.45M compared with $1.86M for Purple Biotech (PPBT).

Are GRI Bio and Purple Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons